Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARCATTO, Leiliane Rodrigues
dc.contributor.authorSACILOTTO, Luciana
dc.contributor.authorDARRIEUX, Francisco Carlos da Costa
dc.contributor.authorHACHUL, Denise Tessariol
dc.contributor.authorSCANAVACCA, Mauricio Ibrahim
dc.contributor.authorKRIEGER, Jose Eduardo
dc.contributor.authorPEREIRA, Alexandre Costa
dc.contributor.authorSANTOS, Paulo Caleb Junior Lima
dc.date.accessioned2016-12-20T16:36:23Z
dc.date.available2016-12-20T16:36:23Z
dc.date.issued2016
dc.description.abstractBackground: Warfarin is the most prescribed oral anticoagulant used for preventing stroke in patients with atrial fibrillation. Time in the therapeutic range (TTR) has been accepted as the best method to evaluate the quality of warfarin therapy. The main aim of the present study was to evaluate the impact of variables on the time in the therapeutic range for warfarin therapy in patients with atrial fibrillation from a referral cardiovascular hospital. Methods: This retrospective study included 443 patients were included (190 patients with age < 65 years and 253 patients with age >= 65 years) from 2011 to 2014 and TTR was computed according to Rosendaal's method. Results: Patients with age >= 65 years had higher TTR value (67+/-22%) compared with patients with < 65 years (60+/-24%) (p = 0.004). In a linear regression model, only age >= 65 years emerged as a significant predictor of greater TTR values. In multivariate logistic regression model, the variable age = 65 years was associated with higher OR for having a TTR higher than the median value (OR = 2.17, p < 0.001). Conclusion: We suggest that the age influenced TTR through greater drug adherence. Strategies for increasing drug adherence might improve quality of warfarin anticoagulation.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP, Brazil [Proc.2013/09295-3]
dc.identifier.citationONCOTARGET, v.7, n.34, p.54194-54199, 2016
dc.identifier.doi10.18632/oncotarget.10944
dc.identifier.issn1949-2553
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/17022
dc.language.isoeng
dc.publisherIMPACT JOURNALS LLC
dc.relation.ispartofOncotarget
dc.rightsopenAccess
dc.rights.holderCopyright IMPACT JOURNALS LLC
dc.subjectwarfarin
dc.subjectTTR
dc.subjectage
dc.subjectatrial fibrillation
dc.subjectpolymorphisms
dc.subjectGerotarget
dc.subject.otherpredicting stroke
dc.subject.otheranticoagulation
dc.subject.othervkorc1
dc.subject.othercyp2c9
dc.subject.othernonadherence
dc.subject.otherevents
dc.subject.otherimpact
dc.subject.otherrace
dc.subject.wosOncology
dc.subject.wosCell Biology
dc.titleAge is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus16
hcfmusp.contributor.author-fmusphcLEILIANE RODRIGUES MARCATTO
hcfmusp.contributor.author-fmusphcLUCIANA SACILOTTO FERNANDES
hcfmusp.contributor.author-fmusphcFRANCISCO CARLOS DA COSTA DARRIEUX
hcfmusp.contributor.author-fmusphcDENISE TESSARIOL HACHUL
hcfmusp.contributor.author-fmusphcMAURICIO IBRAHIM SCANAVACCA
hcfmusp.contributor.author-fmusphcJOSE EDUARDO KRIEGER
hcfmusp.contributor.author-fmusphcALEXANDRE DA COSTA PEREIRA
hcfmusp.contributor.author-fmusphcPAULO CALEB JUNIOR DE LIMA SANTOS
hcfmusp.description.beginpage54194
hcfmusp.description.endpage54199
hcfmusp.description.issue34
hcfmusp.description.volume7
hcfmusp.origemWOS
hcfmusp.origem.pubmed27486984
hcfmusp.origem.scopus2-s2.0-84983479269
hcfmusp.origem.wosWOS:000385435000009
hcfmusp.publisher.cityALBANY
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAgeno W, 2012, CHEST, V141, pE44S, DOI 10.1378/chest.11-2292
hcfmusp.relation.referenceAHMAD S, 1990, ARCH INTERN MED, V150, P2407, DOI 10.1001/archinte.150.11.2407
hcfmusp.relation.referenceAnsell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670
hcfmusp.relation.referenceBhandari VK, 2008, J HEALTH CARE POOR U, V19, P41, DOI 10.1353/hpu.2008.0002
hcfmusp.relation.referenceBlackshear JL, 1996, LANCET, V348, P633
hcfmusp.relation.referenceCaldeira Daniel, 2014, BMC Res Notes, V7, P891, DOI 10.1186/1756-0500-7-891
hcfmusp.relation.referenceCamm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
hcfmusp.relation.referenceChesebro JH, 1996, ARCH INTERN MED, V156, P409
hcfmusp.relation.referenceChugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119
hcfmusp.relation.referenceCohen MJ, 2012, J HOSP MED, V7, P470, DOI 10.1002/jhm.1940
hcfmusp.relation.referenceCotte FE, 2014, CLIN THER, V36, P1160, DOI 10.1016/j.clinthera.2014.07.016
hcfmusp.relation.referenceFEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469
hcfmusp.relation.referenceGage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
hcfmusp.relation.referenceGuyatt GH, 2012, CHEST, V141, pE185S, DOI 10.1378/chest.11-2289
hcfmusp.relation.referenceHuang L.H., 1996, J MED SCI, V12, P423
hcfmusp.relation.referenceJetter A, 2004, EUR J CLIN PHARMACOL, V60, P165, DOI 10.1007/s00228-004-0754-z
hcfmusp.relation.referenceSantos PCJL, 2013, EUR J CLIN PHARMACOL, V69, P789, DOI 10.1007/s00228-012-1404-5
hcfmusp.relation.referenceSantos PCL, 2014, J MANAGE CARE PHARM, V20, P376
hcfmusp.relation.referenceLi C, 2009, BLOOD, V113, P3925, DOI 10.1182/blood-2008-09-176859
hcfmusp.relation.referenceLip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
hcfmusp.relation.referenceMonane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805
hcfmusp.relation.referenceOkumura K, 2011, CIRC J, V75, P2087, DOI 10.1253/circj.CJ-11-0350
hcfmusp.relation.referencePamboukian SV, 2008, CLIN CARDIOL, V31, P30, DOI 10.1002/clc.20175
hcfmusp.relation.referencePastori D, 2015, INT J CARDIOL, V201, P513, DOI 10.1016/j.ijcard.2015.08.054
hcfmusp.relation.referencePsaty BM, 1997, CIRCULATION, V96, P2455
hcfmusp.relation.referenceRose AJ, 2008, J THROMB HAEMOST, V6, P1647, DOI 10.1111/j.1538-7836.2008.03075.x
hcfmusp.relation.referenceROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
hcfmusp.relation.referenceSantos PC, 2015, PHARMACOGENOMICS, V16, P1
hcfmusp.relation.referenceSchwarz UI, 2008, NEW ENGL J MED, V358, P999, DOI 10.1056/NEJMoa0708078
hcfmusp.relation.referenceSconce EA, 2005, BLOOD, V106, P2329, DOI 10.1182/blood-2005-03-1108
hcfmusp.relation.referenceScott SA, 2010, PHARMACOGENOMICS, V11, P781, DOI [10.2217/pgs.10.49, 10.2217/PGS.10.49]
hcfmusp.relation.referenceShen AYJ, 2008, STROKE, V39, P2736, DOI 10.1161/STROKEAHA.107.508580
hcfmusp.relation.referenceSinger DE, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000067
hcfmusp.relation.referenceSkeppholm M, 2014, CLIN RES CARDIOL, V103, P998, DOI 10.1007/s00392-014-0742-y
hcfmusp.relation.referenceWaterman AD, 2004, AM J HEALTH-SYST PH, V61, P1258
hcfmusp.relation.referenceWhite HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239
hcfmusp.relation.referenceWorld Health Organization, DEF OLD ELD PERS
hcfmusp.relation.referenceWitt DM, 2013, THROMB RES, V132, pE124, DOI 10.1016/j.thromres.2013.06.006
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication33472424-dc61-4d3d-bde3-374edf9985b1
relation.isAuthorOfPublicationf8d8f93b-2282-4b79-808f-fefcd71fd451
relation.isAuthorOfPublication58c4e1f0-429b-4e5f-b0d4-542437b39a34
relation.isAuthorOfPublicationa43e8a49-8c91-4c9e-98b6-486483a94e83
relation.isAuthorOfPublication838aea80-1589-4bf2-88eb-fbf1dbdc3db9
relation.isAuthorOfPublicationa970d450-bcd4-4662-94d6-ad1c6d043b3c
relation.isAuthorOfPublication415ce7ca-65c1-4699-b6f4-19dae8b03849
relation.isAuthorOfPublicationc78fbf09-2a91-499f-862e-74830b3b5fab
relation.isAuthorOfPublication.latestForDiscovery33472424-dc61-4d3d-bde3-374edf9985b1
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MARCATTO_Age_is_associated_with_time_in_therapeutic_range_2016.PDF
Tamanho:
656.61 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - ODS/03